Cellestia Biotech is happy to announce that the Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of relapsed-refractory T cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL /LBL) is now open for recruitment.

CB-103 is a small molecule transcriptional pan-NOTCH inhibitor with a novel mechanism of action. A Phase I clinical trial has shown promising safety and tolerability, proof of biological activity, and signs of efficacy. A new investigator- initiated trial (IIT) is starting at The University of Texas MD Anderson Cancer Center, in the departments of Pediatrics and Adult Leukemia, to combine the potential of NOTCH and BCL2 inhibition considering the biological synergies between the two pathways. CB-103, in combination with Venetoclax, will be tested for the treatment of relapsed-refractory T cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/LBL in patients 12-40 years old). Added to the ongoing anti-leukemia treatment, CB-103 administration to a r/r T-ALL patient under a compassionate use program resulted in a complete response making the patient eligible for Hematopoietic Stem Cell Transplant. The IIT trial at MD Anderson is now open for patient recruitment.

Please see here the link to the paper for your read.